title: [Erysipelatous inflammation: a new view on a long-standing problem].
abstract: Under observation there were 72 patients with primary and recurring forms of erysipelatous inflammation. The data obtained have shown the reliable (p<0.001) effectiveness of antimitotic treatment with terbinaphin hydrochloride (lamizil) for prophylactics of recurrences of erysipelatous inflammation: the frequency of recurrences in the group of the treatment was 7.1%, in the control group it was 45.5%.
authors.forename: S A
authors.initials: SA
authors.lastname: Shliapnikov
authors.forename: N R
authors.initials: NR
authors.lastname: Naser
authors.forename: S R
authors.initials: SR
authors.lastname: Eremin
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use; D004886:Erysipelas / Q000188:drug therapy / Q000382:microbiology* / Q000534:rehabilitation; D005260:Female; D006760:Hospitalization; D006801:Humans; D035002:Lower Extremity / Q000382:microbiology*; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use; D000077291:Terbinafine
chemical_list: D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine